GH Stock Recent News

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wi.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. Guardant Health's management is scheduled to participate in a fireside chat on Thursday, September 5th at 11:30 a.m. ET. Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.gua.

Guardant Health announced plans to sell stock and raise $400 million in new cash. Guardant burned through nearly $300 million over the past year, so the new fund raise should cover about 16 months of cash burn.

Wood added to her positions in Ibotta, Roblox, and Guardant Health on Thursday. Ibotta has taken a hit after its first two quarters as a public company.

After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Guardant Health (GH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.67 per share a year ago.

Beyond analysts' top -and-bottom-line estimates for Guardant Health (GH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Cathie Wood bought shares of Guardant Health, Oklo, and CRISPR Technologies on Tuesday. Guardant is the only one of the three trading higher this year, fueled by the prospects of a new colorectal cancer screening tool.